GALT · Galectin Therapeutics Inc
United States · RS rating 64 · As of 2026-11-03
| Price | 3.35 USD |
|---|---|
| 1-day change | +0.6% |
| RS rating (overall / 1M / 3M / 12M) | 64 / 35 / 80 / 25 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 24 / 26 / 32 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -75.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +48.5% |
| Market cap (USD) | $156.0M |